The radiopharmaceutical is a positron emission tomography myocardial perfusion imaging agent used in patients with known or suspected coronary artery disease, according to a Feb. 25 news release from GE Healthcare.
Flyrcado received FDA approval Sept. 27, and it is expected to be available to all U.S. cardiac positron emission tomography centers by the end of 2025, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.